{{flagHref}}
Products
  • Products
  • Categories
  • Blog
  • Podcast
  • Application
  • Document
|
/ {{languageFlag}}
Select language
Stanford Advanced Materials {{item.label}}
Stanford Advanced Materials
Select language
Stanford Advanced Materials {{item.label}}
a

LMD-13. ReSPECT-LM: Maximum tolerated dose, safety, and efficacy of intraventricular Rhenium-186 Nanoliposome (186RNL) for leptomeningeal metastases

Title LMD-13. ReSPECT-LM: Maximum tolerated dose, safety, and efficacy of intraventricular Rhenium-186 Nanoliposome (186RNL) for leptomeningeal metastases
Authors Andrew Brenner, John Floyd, Ande Bao, William Phillips, Gregory Stein
Magazine Neuro-oncology Advances
Date 08/09/2021
DOI 10.1093/noajnl/vdab071.038
Introduction Leptomeningeal metastases (LM) are a severe complication of advanced cancer affecting the central nervous system. Novel approaches are essential to enhance survival and quality of life. Rhenium-186 NanoLiposome (186RNL) enables targeted delivery of beta-emitting radiation to tumours. In a Phase 1 trial with recurrent glioblastoma patients, the mean absorbed dose for 75% tumour coverage was 392 Gy. The treatment showed tolerable adverse effects, with cerebral oedema resolving post-steroid treatment. This two-part Phase 1 study aims to determine the safety and maximum tolerated dose of 186RNL in LM patients, followed by efficacy assessment in breast and lung cancer cohorts. The primary focus is on anti-tumour activity, with secondary endpoints evaluating pharmacokinetics, dosimetry, and survival rates. Enrollment is set to commence in the second half of 2021.
Quote Andrew Brenner, John Floyd and Ande Bao et al. LMD-13. ReSPECT-LM: Maximum tolerated dose, safety, and efficacy of intraventricular Rhenium-186 Nanoliposome (186RNL) for leptomeningeal metastases. Neuro-oncology Advances. 2021. Vol. 3(Suppl 3):iii10-iii10. DOI: 10.1093/noajnl/vdab071.038
Materials Nanocomposites
Industry Pharmaceutical Industry
Related papers
Loading... Please wait...
Publish your research and articles on the SAM website
Disclaimer
This site only provides metadata for academic works to enable users to easily find relevant information. For full access to the works, please use the DOI to visit the original publisher's website. The data comes from publicly accessible scientific databases and complies with the terms of use of these platforms. If you have any concerns regarding copyright, please contact us. We will address them immediately.

Success! You are now subscribed.

You have successfully subscribed! Check your inbox soon to receive great emails from this sender.
Leave A Message
Leave A Message
* Your Name:
* Your Email:
* Product Name:
* Your Phone:
* Comments: